Retatrutide

Retatrutide is an investigational synthetic peptide that activates three incretin and metabolic receptors at once — GIP, GLP-1, and glucagon. It is the next-generation extension of the dual-agonist concept that tirzepatide pioneered, and it is currently the subject of pharmaceutical clinical trials.

Because retatrutide has not been approved as a finished pharmaceutical at the time of writing, it is encountered almost exclusively as a lyophilized research-grade peptide in milligram-rated vials. Common vial sizes in the research market range from 5 mg to 20 mg or larger.

Like the other long-acting incretin peptides on this site, retatrutide is typically logged on a once-weekly cadence. The weekly rhythm shapes how vials are reconstituted, how doses escalate over time, and how vial duration is estimated for refill planning.

Retatrutide is a purely investigational peptide currently undergoing Phase 3 clinical trials. As of the latest public data, it has not received regulatory approval from the FDA or any other global health authority. This status fundamentally frames any personal research or tracking project, as there is no established prescribing information, standard of care, or approved dosing protocol. All available quantitative data on dose structures and administration schedules are derived exclusively from published clinical trial documentation, which individuals may study to plan their own data-logging activities.

The primary focus of scientific inquiry into retatrutide is its unique molecular structure as a triple-hormone-receptor agonist. Unlike its predecessors, which target one or two metabolic hormone pathways, this peptide is designed to interact with three distinct receptors. This novel multi-agonist approach is the central feature distinguishing it within the class of incretin mimetics and related metabolic compounds. Understanding this tricycle mechanism is foundational to documenting its observed attributes in a personal tracking log and differentiating it from other peptides in the same category.

Retatrutide binds to the GIP, GLP-1, and glucagon receptors. The first two are familiar from semaglutide and tirzepatide; the addition of glucagon-receptor activation is what differentiates retatrutide from those earlier peptides and is the focus of much of its ongoing clinical research.

Triple-receptor activation produces metabolic effects that are still being characterized in published trials. Anyone tracking retatrutide in a personal log should pair the dose history with weekly metrics like weight, hunger ratings, and side-effect notes — that pairing is what turns a list of injections into a usable trend.

The compound's pharmacology is defined by its activity as a single-molecule agonist for the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. While co-activation of GLP-1 and GIP receptors is also the mechanism of tirzepatide, the addition of the glucagon receptor agonist component is what makes retatrutide a distinct investigational agent. In metabolic physiology, glucagon signaling is traditionally associated with stimulating the liver to produce glucose. However, researchers are studying how its concurrent activation with potent incretin mimetics like GLP-1 and GIP might influence energy expenditure, lipid metabolism, and appetite signaling in ways that are distinct from single- or dual-agonist peptides.

Once-weekly subcutaneous injection is the default cadence in most retatrutide logs. Each draw is small enough that a U-100 insulin syringe is the standard tool — the volumes involved are too small to read accurately on a tuberculin syringe.

Because retatrutide is potent at small milligram counts, dose escalation tends to be gradual and well-tracked. The exact week and unit count of each step is the kind of information that is hard to reconstruct from memory months later, which is why a structured dose log is more durable than scattered notes.

Dosing schedules documented in published Phase 2 clinical trials for retatrutide have involved a notably steep titration. Study protocols have detailed starting doses that escalate at predetermined intervals to much higher terminal doses than those typical for related peptides. For example, a documented titration schedule involved monthly escalations from a starting dose, progressing through tiers such as 2 mg, 4 mg, 8 mg, and up to a 12 mg maximum dose, all administered on a weekly cadence. For personal tracking, these published trial schedules are the only available structural reference points for logging dose escalation over a period of months.

The illustrative example on this page assumes a 10 mg vial reconstituted with 2 mL of bacteriostatic water. That produces a concentration of 5 mg per mL, which makes a 2 mg illustrative dose exactly 0.4 mL — 40 units on a U-100 syringe.

Larger vials of retatrutide benefit from larger diluent volumes for the same reason any peptide does: per-dose draws land on cleaner, easier-to-read unit counts on the syringe. A 20 mg vial reconstituted with 4 mL of bacteriostatic water gives the same per-dose unit count as a 10 mg vial with 2 mL, just over twice as many total doses.

The larger dose magnitudes studied in retatrutide trials introduce practical considerations for reconstitution and administration volume. Higher doses, such as the 8 mg or 12 mg levels observed in trial publications, require careful planning to manage the volume drawn for injection. For instance, using a standard reconstitution of a 10 mg vial with 2 mL of bacteriostatic water results in a concentration of 5 mg/mL. At this concentration, drawing a 12 mg dose would require a volume of 2.4 mL. This volume exceeds the capacity of a standard 1 mL U-100 insulin syringe and would necessitate either multiple separate injections or the use of a larger syringe, such as a 3 mL syringe, for a single administration. Planning reconstitution concentration with the final target dose in mind is critical for managing injection logistics.

Lyophilized retatrutide powder is typically stored refrigerated until reconstitution. Once reconstituted, the in-use vial is generally kept refrigerated and used within several weeks. Marking the reconstitution date directly on the vial is the simplest way to avoid using a long-opened vial past its useful life.

Because retatrutide is investigational, careful logging is even more valuable than usual: pairing dose, escalation date, weight, hunger ratings, and side effects produces a record that is genuinely useful both to the individual and to a healthcare professional reviewing the history later.

Given the aggressive dose-escalation schedules observed in clinical trial data, detailed titration-schedule logging is an even more important component of personal data collection than for other incretin mimetics. A personal log should not only record the dose amount but also meticulously document the date of each upward titration. Tracking how the subject responds to each new dose level—for example, the transition from 4 mg to 8 mg—provides a granular dataset. This documentation allows for a clear audit of the titration velocity and helps contextualize any observations logged during the period, associating them with a specific, time-stamped dose level within the rapid escalation structure being studied.